期刊
EUROPEAN UROLOGY
卷 56, 期 1, 页码 207-211出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2009.01.001
关键词
Bevacizumab; Renal cell carcinoma; Salvage therapy; Sunitinib
We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile. Crown Copyright (C) 2009 Published by Elsevier B.V. on behalf of European Association of Urology. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据